PAM
KNSA icon

Panagora Asset Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Panagora Asset Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-4,308
Closed -$67K – 2605
2020
Q1 		$67K Buy
+4,308
New +$67.4K ﹤0.01% 1815

Other funds holding KNSA

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Panagora Asset Management's KNSA Position: Q2 2020 in Review

Panagora Asset Management sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2020, closing a stake of 4,308 shares — an estimated $67K sold.

Panagora Asset Management first reported a position in KNSA in Q1 2020 and held it in 1 quarter. The position peaked at $67K in Q1 2020. 96 funds tracked by Wall St. Rank hold KNSA as of Q2 2020.

  • Panagora Asset Management reported no remaining Kiniksa Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Panagora Asset Management sold 4,308 Kiniksa Pharmaceuticals shares in Q2 2020, an estimated $67K.
  • Panagora Asset Management first reported a position in Kiniksa Pharmaceuticals in Q1 2020 and held it in 1 quarter.
  • Panagora Asset Management's Kiniksa Pharmaceuticals position peaked at $67K in Q1 2020.
  • 96 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2020.

Based on Panagora Asset Management's 13F filing for Q2 2020, filed 12 Aug 2020.